Ryan W. Huey, MD, MS

Peer-Reviewed Articles

1. Pizuorno Machado, A, Adames, SM, Shatila, M, Aujla, P, Huey, RW, Wang, Y, Thomas, AS. Immune checkpoint inhibitor-associated gastrointestinal adverse events in patients with colorectal cancer. Annals of Gastroenterology 38(1):72-79, 2025. e-Pub 2025. PMID: 39802282.
2. Bhamidipati, D, Johnson, JR, Lin, K, Pelicano, H, Eng, C, Huey, RW, Wolff, RA, Halperin, DM, Frumovitz, M, Wistuba, II, Duose, D, Mallampati, S, Luthra, R, Morris, VK. The Clinical Utility of a Next-Generation Sequencing-Based Approach to Detecting Circulating HPV DNA in Patients with Advanced Anal Cancer. Cancers 17(2), 2025. e-Pub 2025. PMID: 39858090.
3. Yousef M, Yousef A, Chowdhury S, Fanaeian MM, Knafl M, Peterson J, Zeineddine M, Alfaro K, Zeineddine F, Goldstein D, Hornstein N, Dasari A, Huey R, Johnson B, Higbie V, Bent A, Kee B, Lee M, Morelli MP, Morris VK, Halperin D, Overman MJ, Parseghian C, Vilar E, Wolff R, Raghav KP, White MG, Uppal A, Sun R, Wang W, Kopetz S, Willis J, Shen JP. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncol 10(11), 2024. e-Pub 2024. PMID: 39264607.
4. Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker C, Medina-Rosales MN, Reuben A, Holliday EB, Smith GL, Noticewala SS, Nicholas S, Price TR, Martin-Paulpeter RM, Perles LA, Lee SS, Lee MS, Smaglo BG, Huey RW, Willis J, Zhao D, Cohen L, Taniguchi CM, Koay EJ, Katz MHG, Wolff RA, Das P, Pant S, Koong AC, Tang C. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. J Clin Oncol 42(32):JCO2400081, 2024. e-Pub 2024. PMID: 39102622.
5. Cass SH, Tzeng CD, Prakash LR, Maxwell J, Snyder RA, Kim MP, Huey RW, Smaglo BG, Pant S, Koay EJ, Wolff RA, Lee JE, Katz MHG, Ikoma N. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Ann Surg. e-Pub 2024. PMID: 38506042.
6. Johnson B, Morris V, Wang X, Dasari A, Raghav K, Shen JP, Lee MS, Huey R, Parseghian C, Willis J, Wolff R, Drusbosky LM, Overman MJ, Kopetz S. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling. Cancers (Basel) 16(4), 2024. e-Pub 2024. PMID: 38398128.
7. Huey RW, Shah AT, Reddi HV, Dasari P, Topham JT, Hwang H, Dhillon N, Willett A, Smaglo BG, Estrella JS, Rashid A, Matamoros A, Overman MJ, Choquette L, Omerza G, Kelly K, Wang X, Loree JM, Rueter J, Varadhachary GR, Raghav K. Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study. JournL National Cancer Inst 115(8):994-997, 2023. e-Pub 2023. PMID: 37202363.
8. Morris VK, Jazaeri A, Westin SN, Pettaway C, George S, Huey RW, Grinsfelder M, Shafer A, Johnson B, Vining D, Guo M, Fellman B, Frumovitz M. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist 28(7):618-623, 2023. e-Pub 2023. PMID: 37104874.
9. Rogers JE, Sirisaengtaksin A, Leung M, Morris VK, Xiao L, Huey R, Wolff R, Eng C, Vauthey JN, Tzeng CD, Johnson B. Hepatic Metastasectomy in Squamous Cell Carcinoma of the Anal Canal: A Case Series of a Curative Approach. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568706.
10. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precision Oncology 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
11. Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist 27(11):952-957, 2022. e-Pub 2022. PMID: 35946836.
12. Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
13. Parseghian CM, Sanchez EV, Sun R, Eluri M, Morris VK, Johnson B, Morelli MP, Overman MJ, Willis J, Huey R, Singh Raghav KP, Dasari A, Kee BK, Wolff RA, YC Shen JP, Kopetz S. Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. Journal of Clinical Oncology 40(16_suppl):3520-3520, 2022. e-Pub 2022.
14. Johnson B, Yang D, Dada HI, Morris VK, Wang X, Dasari A, Singh Raghav KP, Kee BK, YC Shen JP, Huey R, Lee MS, Parseghian CM, Le P, Morelli MP, Willis J, Wolff RA, Drusbosky L, Overman MJ, Kopetz S. RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. Journal of Clinical Oncology 40(16_suppl):3592-3592, 2022. e-Pub 2022.
15. Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer 10(5), 2022. e-Pub 2022. PMID: 35618285.
16. Morris, VK, Overman, MJ, Lam, MC, Parseghian, C, Johnson, B, Dasari, NV, Raghav, KS, Kee, BK, Huey, RW, Wolff, RA, Shen, JY, Li, J, Zorrilla, I, Tzeng, CD, Tran Cao, HS, Chun, YS, Newhook, TE, Vauthey, JN, Duose, D, Luthra, R, Haymaker, CL, Kopetz, S. Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. Cancer Research Communications 2(9):979-986, 2022. e-Pub 2022.
17. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist 26(7):588-596, 2021. e-Pub 2021. PMID: 33783054.
18. Raghav K, Hwang H, Jácome AA, Bhang E, Willett A, Huey RW, Dhillon NP, Modha J, Smaglo B, Matamoros A, Estrella JS, Jao J, Overman MJ, Wang X, Greco FA, Loree JM, Varadhachary GR. Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. Clinical Cancer Research 27(12):3414-3421, 2021. e-Pub 2021. PMID: 33858857.
19. Allen CJ, Eska JS, Thaker NG, Feeley TW, Kaplan RS, Huey RW, Tzeng CD, Lee JE, Frank SJ, Aloia TA, Gottumukkala V, Katz MHG. Developing a Value Framework: Utilizing Administrative Data to Assess an Enhanced Care Initiative. Journal of Surgical Research 262:115-120, 2021. e-Pub 2021. PMID: 33561722.
20. Huey RW, Smaglo BG, Estrella JS, Matamoros A, Overman MJ, Varadhachary GR, Raghav KPS. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait. Oncologist 26(4):e650-e657, 2021. e-Pub 2021. PMID: 33524217.
21. Middleton, LP, Huey, RW, Medeiros, LJ, Miranda, R. Follicular dendritic cell sarcoma in the differential diagnosis of GATA3 positive tumors. Human Pathology: Case Reports 23, 2021. e-Pub 2021.
22. Augustyn A, Reed VI, Ahmad N, Bhutani MS, Bloom ES, Bowers JR, Chronowski GM, Das P, Holliday EB, Delclos ME, Huey RW, Koay EJ, Lee SS, Nelson CL, Taniguchi CM, Koong AC, Chun SG. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. Clinical Translational Radiation Oncology 27:147-151, 2021. e-Pub 2021. PMID: 33665384.
23. Allen CJ, Thaker NG, Prakash L, Kruse BC, Feeley TW, Kaplan RS, Huey R, Frank SJ, Aloia TA, Gottumukkala V, Katz MHG. Communicating Value: Use of a Novel Framework in the Assessment of an Enhanced Recovery Initiative. Ann Surg 273(1):e7-e9, 2021. e-Pub 2021. PMID: 32568750.
24. Huey RW, Makawita S, Xiao L, Matamoros A, Estrella JS, Overman MJ, Varadhachary GR, Raghav K. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer 19(1):965, 2019. e-Pub 2019. PMID: 31623602.
25. Teague TK, Tan C, Marino JH, Davis BK, Taylor AA, Huey RW, Van De Wiele CJ. CD28 expression redefines thymocyte development during the pre-T to DP transition. Int Immunol 22(5):387-97, 2010. e-Pub 2010. PMID: 20203098.

Other Articles

1. Selig BP, Furr JR, Huey RW, Moran C, Alluri VN, Medders GR, Mumm CD, Hallford HG, Mulvihill JJ Cancer chemotherapeutic agents as human teratogens. Birth Defects Res A Clin Mol Teratol 94(8):626-50, 2012. PMID: 22851372.

Editorials

1. Lyu HG, Gordon WJ, Huey RW, Katz MHG. Leveraging the 21st Century Cures Act to Improve Cancer Care, Patient Engagement, and Data Collection. JCO Oncology Practice 18(12):788-790, 2022. PMID: 36219810.
2. Huey RW, Hawk E, Offodile AC. Mind the Gap: Precision Oncology and Its Potential to Widen Disparities. J Oncol Pract 15(6):301-304, 2019. PMID: 31112478.

Abstracts

1. Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. Journal for immunotherapy of cancer 10(5), 2022. e-Pub 2022. PMID: 35618285.
2. Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer 10(5), 2022. e-Pub 2022. PMID: 35618285.
3. Chun S, Augustyn A, Reed V, Ahmad N, Bhutani M, Bloom ES, Bowers J, Chronowski G, Das P, Holliday E, Delclos M, Huey R, Koay EJ, Lee S, Nelson C, Taniguchi C, Koong A. Implementation of a Stereotactic Body Radiotherapy Program for Unresectable Pancreatic Cancer in an Integrated Community Academic Radiation Oncology Satellite Network. Cureus Journal of Medical Science 14(2), 2022. e-Pub 2022.
4. Morris VK, Parseghian CM, Escano M, Johnson B, Singh Raghav KP, Dasari A, Huey R, Overman MJ, Willis J, Lee MS, Wolff RA, Kee BK, YC Shen JP, Morelli MP, Tam A, Foo WC, Xiao L, Kopetz S. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer 40(4_suppl):12-12, 2022. e-Pub 2022.
5. Huey RW, Estrella JS, Higbie VS, Le P, Bent A, Matamoros A, Lano E, Willett A, Nguyen V, Escano-Caballero M, Wilson K, Lin H, Raghav K. Phase II Trial of Sintilimab in Cancer of Unknown Primary. 2025 GI ASCO.
6. Huey R, George G, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Ahnert JR, Meric-Bernstam F, Shih YT, Hong DS. Out of pocket costs and financial toxicity experienced by patients in early phase clinical trials. 2019 ASCO Annual Meeting I.
7. Huey R, Anand S, Rogers JE, Dasari A, Varadhachary GR, Gothwal A, Loree JM, Ellis LM, Overman MJ, Singh Raghav KP. Value appraisal of FDA approved cancer drugs over the past decade. ASCO Quality Care Symposium.
8. Morris VK, Singh Raghav KP, Dasari A, Overman MJ, Kee BK, Johnson B, Parseghian CM, YC Shen JP, Huey R, Raymond VM, Duose DY, Luthra R, Hong DS, Janku F, Kopetz S. Utility of circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer. Colorectal Cancer.
9. Piha-Paul S, Tsimberidou A, Janku F, Raghav K, Wolff R, Huey R, Peng P, Levin W, Ngo B, Wang H, Sun C, Ru Q, Wu F, Javle M. P-261 Phase I study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma.
10. Shah AT, Huey R, Dasari P, Willett A, Smaglo BG, Matamoros A, Overman MJ, Estrella J, Singh Raghav KP. Cancer of unknown primary with gastrointestinal profiles: A favorable CUP subset. Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary.
11. Shah AT, Huey R, Dasari P, Willett A, Smaglo BG, Matamoros A, Overman MJ, Estrella J, Singh Raghav AKP. Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset. Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary.
12. Johnson B, Yang D, Dada HI, Morris VK, Wang X, Dasari A, Singh Raghav KP, Kee BK, YC Shen JP, Huey R, Lee MS, Parseghian CM, Le P, Morelli MP, Willis J, Wolff RA, Drusbosky L, Overman MJ, Kopetz S. RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. Gastrointestinal Cancer—Colorectal and Anal.
13. Parseghian CM, Sanchez EV, Sun R, Eluri M, Morris VK, Johnson B, Morelli MP, Overman MJ, Willis J, Huey R, Singh Raghav KP, Dasari A, Kee BK, Wolff RA, YC Shen JP, Kopetz S. Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. Gastrointestinal Cancer—Colorectal and Anal.
14. Johnson B, Haymaker C, Morris VK, Dasari A, Higbie VS, Shen JP, Parseghian C, Morelli MP, Huey R, Lee MS, Willis J, Raghav KP, Yuan Y, Zebala J, DePinho RA, Kopetz S, Overman M. Abstract CT118: A phase I/II trial of a CXCR1/2 inhibitor in combination with anti-PD-1 for circulating tumor DNA (ctDNA) positive & refractoryRAS-mutated microsatellite stable (MSS) colorectal cancer.
15. Rivers Z, Huey RW, Ben-Shachar R, Avadhani AN, Taxter TJ, Beauchamp KA, Hockenberry AJ, Nimeiri H, Allam J, Kalyan A, Singh Raghav KP, Lee MS. Molecular diagnostic classification for cancers of unknown primary (CUP): Post-testing diagnosis and treatment impact analysis from real-world claims data. Health Services Research and Quality Improvement.
16. Dasari A, Bent AH, Alfaro-Munoz K, Huey RW, Johnson B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian CM, Singh Raghav KP, Shen J, Willis J, Newhook TE, Uppal A, You Y, Konishi T, Chang GJ, Kopetz S, Wolff AR. Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC). Gastrointestinal Cancer—Colorectal and Anal.
17. Johnson :B, Pelicano H, Huey RW, Wolff RA, Wistuba II, Duose DY, Mallampati S, Luthra R, K Morris AV. HPV integration as a prognostic biomarker for metastatic anal cancer: A next-generation sequencing ctDNA-based approach. Gastrointestinal Cancer—Colorectal and Anal.
18. Smaglo BG, LeBleu VS, Lee J, Maitra A, Kalluri R, Rezvani K, Solis Soto LM, Hurd M, Kaur I, Mendt Vilchez MC, Kirtley ML, Shaftoe SL, Morelli MP, Overman MJ, Zhou D, Wolff RA, Tu J, Willis JA, Huey RW, Lee MS, Bhosale PR, Dworsky SW, Xu L, Pant S, Shpall EJ. Abstract C084: iExplore: A phase I study of mesenchymal stem cell derived exosomes with KrasG12D siRNA for metastatic pancreas cancer patients harboring the KrasG12D mutation.
19. Higbie :V, Shah P, Bent AH, Dasari A, Huey RW, Johnson B, Kee BK, ALL … …S, J Overman AM. Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade: A single center retrospective analysis. 2024 ASCO Gastrointestinal Cancers Symposium.
20. Andrew Jared Pellatt, Giulia Maddalena, Madhulika Eluri, Christine Megerdichian Parseghian, Kathryn Aziz, Kristin Alfaro, Robert J Kell, Alisha Heather Bent, Ryan W. Huey, Abhineet Uppal, Tsuyoshi Konishi, Michael J Overman, Maria Pia Morelli, Jason Willis, John Paul YC Shen, Kanwal Pratap Singh Raghav, Timothy E Newhook, Van K Morris, Arvind Dasari, Scott Kopetz. Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease. 2024 ASCO Gastrointestinal Cancers Symposium.
21. Pellatt AJ, Bent AH, Parseghian CM, Johnson B, Huey RW, Singh Raghav KP, Morris VK, Overman MJ, Morelli MP, Willis J, Le P, YC Shen JP, Lee MS, Alfaro K, Aziz K, Kell RJ, Sun R, Kopetz S, Dasari AA. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy. 2024 ASCO Gastrointestinal Cancers Symposium.
22. Huey RW, Allam J, Ma L, Estrella J, Willett A, Beaty KA, Matamoros A, Lano EA, Fournier KF, Treuner K, Singh Raghav KP, W Huey AR. Utility of gene expression–based cancer classification in diagnosis of malignant peritoneal mesothelioma (MPeM): Filling in the gaps in standard pathologic work-up for a rare cancer. 2024 ASCO Gastrointestinal Cancers Symposium.
23. Maddalena G, Pellatt AJ, Eluri M, Parseghian CM, Aziz K, Alfaro K, Kell RJ, Bent AH, Huey RW, Uppal A, Konishi T, Overman MJ, Morelli MP, Willis J, YC Shen JP, Singh Raghav KP, Newhook TE, Morris VK, Dasari A, Kopetz AS. INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort. 2024 ASCO Gastrointestinal Cancers Symposium.
24. Allam J, Zhao J, Estrella JS, Hwang H, Higbie VS, Willett AF, Matamoros A, Lano E, Raghav K, Huey RW. Clinical Characterization and Outcomes of Patients with PAX8 Positive Cancer of Unknown Primary: a Distinct Immunophenotypic Subset. 2024 ESMO Asia.
25. Allam J, Ma L, Zhao J, Estrella J, Higbie V, Willett A, Matamoros A, Lano E, Treuner K, Raghav K, Huey RW. Clinicopathological characteristics of cancer of unknown primary (CUP) with renal profile using gene expression profiling (GEP) based cancer classification. 2025 GU ASCO.

Book Chapters

1. Huey, RW, Raghav, KS. Treatment Refractory Metastatic Colorectal Cancer, 287-292, 2022.
2. Varadhachary GV, Raghav KP, Huey RW. Carcinoma of Unknown Primary.
3. SiBrito SR, Huey RW. Cancer of Unknown Primary Site. In: The MD Anderson Surgical Oncology Manual. 7. Wolters Kluwer.
4. Allen CJ, Chen A, Huey RW, Shih YT. Value-Based Oncology.

Letters to the Editor

1. Huey, RW, Raghav, KS. Site-specific or empirical chemotherapy for cancer of unknown primary. The lancet oncology 25: e529, 2024.